Naslov
A summary of current NKG2D-based CAR clinical trials

Autori
Curio, Sophie ; Jonsson, Gustav ; Marinović, Sonja

Kolaboracija
Young European Federation of Immunological Societies (yEFIS)

Izvornik
Immunotherapy Advances (2732-4303) 1 (2021), 1; Ltab018, 8

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
NKG2D ; CAR T cells ; immunotherapy ; adoptive cell transfer

Sažetak
Cancer immunotherapies have significantly improved patient survival and treatment options in recent years. Nonetheless, the success of immunotherapy is limited to certain cancer types and specific subgroups of patients, making the development of new therapeutic approaches a topic of ongoing research. Chimeric antigen receptor (CAR) cells are engineered immune cells that are programmed to specifically eliminate cancer cells. Ideally, a CAR recognizes antigens that are restricted to tumor cells to avoid off-target effects. NKG2D is an activating immunoreceptor and an important player in anti-tumor immunity due to its ability to recognize tumor cells and initiate an anti- tumor immune response. Ligands for NKG2D are expressed on malignant or stressed cells and typically absent from healthy tissue, making it a promising CAR candidate. Here, we provide a summary of past and ongoing NKG2D-based CAR clinical trials and comment on potential pitfalls.

Izvorni jezik
Engleski

Znanstvena područja
Biologija

POVEZANOST RADA